Drugs / PU-H71
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03935555 | Aug 2019 → Oct 2022 | myelofibrosis, primary myelofibrosis | Samus Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03373877 | May 2018 → Oct 2019 | myelofibrosis, primary myelofibrosis | Samus Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03166085 | May 2017 → Dec 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01393509 | Jul 2011 → Mar 2023 | lymphoma, metastatic neoplasm, myeloproliferative neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01581541 | Apr 2011 → Sep 2014 | cancer, lymphoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05612633 | Jun 2022 → Dec 2023 | myeloproliferative neoplasm | Samus Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PU-H71 | “A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN” NCT05612633 ↗ |
| Known as | zelavespib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05612633 ↗ |
| Action | Inhibit | “PU-H71 blocks a protein called Heat Shock Protein-90 (Hsp90).” NCT01393509 ↗ |
| Modality | Small molecule | “PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).” NCT03935555 ↗ |
| Route | Intravenous | “PU-H71 will be administered as an intravenous infusion over 1 hour” NCT01393509 ↗ |